TGFB1 and neoplasm: Mariathasan et al. found that TGF-β was highly expressed in tumor tissues of patients who showed no response to the immune checkpoint inhibitor atezolizumab, suggesting that primary drug resistance against the immune checkpoint inhibitor might be related to the TGF-β pathway (70).